FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) expects the commercialization of GAMMAGARD LIQUID ERC to start in the US in 2026.

Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has accepted their supplemental new drug application (sNDA) for INQOVI ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds.

Taiho Oncology and Taiho Pharmaceutical Announce U.S. FDA Acceptance of Supplemental New Drug Application for INQOVI® in Combination with Venetoclax to Treat Patients with Acute Myeloid Leukemia ...

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. ( ), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases.

Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company ...

How will FDA changes reshape drug approval in 2025 and beyond? Vaccines and complex biologics may face greater headwinds as processes change at a short-staffed agency ...

Fasikl Receives FDA Clearance for Felix NeuroAI Wristband, the First and Only AI-Powered Treatment for Essential Tremor Powered by recent breakthroughs in AI technologies, Felix offers a ...

The FDA cracked down on two plants in India and one in Korea in separate recently released reports, citing issues ranging from mold to skirted testing procedures. | The FDA listed observations at ...

Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.